{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:36:32Z","timestamp":1791380192213,"version":"4.3.3"},"reference-count":31,"publisher":"Japan Atherosclerosis Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2024,11,1]]},"DOI":"10.5551\/jat.64896","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T22:11:51Z","timestamp":1716243111000},"page":"1620-1633","source":"Crossref","is-referenced-by-count":13,"title":["Comparison of Efficacy between Pemafibrate and Omega-3-Acid Ethyl Ester in the Liver: the PORTRAIT Study"],"prefix":"10.5551","volume":"31","author":[{"given":"Yoshio","family":"Sumida","sequence":"first","affiliation":[{"name":"Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ogaki Municipal Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Ogaki Municipal Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kimoto","sequence":"additional","affiliation":[{"name":"Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiomi","family":"Nakade","sequence":"additional","affiliation":[{"name":"Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoaki","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Osonoi","sequence":"additional","affiliation":[{"name":"Nakakinen Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Yoneda","sequence":"additional","affiliation":[{"name":"Division of Hepatology and Pancreatology, Department of Internal Medicine, Aichi Medical University"},{"name":"Goryokai Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Rinella ME, Lazarus JV, Ratziu V et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol, 2023; 79: 1542-1556","DOI":"10.1097\/HEP.0000000000000696"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Targher G, Kendrick J, Smits G, Chonchol M. Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the national health and nutrition examination survey 2001\u20132006. Nutr Metab Cardiovasc Dis, 2010; 20: 583-590","DOI":"10.1016\/j.numecd.2009.05.012"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care, 2007; 30: 2940-2944","DOI":"10.2337\/dc07-0792"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Akbar DH, Kawther AH. Nonalcoholic fatty liver disease in Saudi type 2 diabetic subjects attending a medical outpatient clinic: Prevalence and general characteristics. Diabetes Care, 2003; 26: 3351-3352","DOI":"10.2337\/diacare.26.12.3351-a"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol, 2004; 19: 854-858","DOI":"10.1111\/j.1440-1746.2004.03312.x"},{"key":"6","unstructured":"6) The Japanese Society of Gastroenterology. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2014. Nankodo, 2014"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 2012; 55: 2005-2023","DOI":"10.1002\/hep.25762"},{"key":"8","unstructured":"8) National Institute for Health and Care Excellence. on-Alcoholic Fatty Liver Disease: Assessment and Management. NICE guideline, https: \/\/www.nice.org.uk\/guidance\/ng49 [NG49]; 2016"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016; 64: 73-84","DOI":"10.1002\/hep.28431"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: A multicenter large retrospective study. J Gastroenterol, 2012; 47: 586-595","DOI":"10.1007\/s00535-012-0533-z"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Williams R, Ashton K, Aspinall R, Bellis MA, Bosanquet J, Cramp ME et al. Implementation of the Lancet Standing Commission on Liver Disease in The UK. Lancet, 2015; 386: 2098-2111","DOI":"10.1016\/S0140-6736(15)00680-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Vernon G, Baranova A, Younossi ZM. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther, 2011; 34: 274-285","DOI":"10.1111\/j.1365-2036.2011.04724.x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology, 2010; 52: 79-104","DOI":"10.1002\/hep.23623"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the Welcome* study. Hepatology, 2014; 60: 1211-1221","DOI":"10.1002\/hep.27289"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Shiba K, Tsuchiya K, Komiya C, Miyachi Y, Mori K, Shimazu N et al. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci Rep, 2018; 8: 2362","DOI":"10.1038\/s41598-018-19658-7"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Fujimori N, Tanaka N, Kimura T, Sano K, Horiuchi A, Kato N et al. Long-term luseogliflozin therapy improves histological activity of non-alcoholic steatohepatitis accompanied by type 2 diabetes mellitus. Clin J Gastroenterol, 2020; 13: 83-89","DOI":"10.1007\/s12328-019-01018-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol, 2015; 62: 720-733","DOI":"10.1016\/j.jhep.2014.10.039"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S et al. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: A multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb, 2018; 25: 521-538","DOI":"10.5551\/jat.44412"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Honda Y, Kessoku T, Ogawa Y, Tomeno W, Imajo K, Fujita K et al. Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis. Sci Rep, 2017; 7: 42477","DOI":"10.1038\/srep42477"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H et al. Effects of K-877, a novel selective PPARalpha modulator (SPPARM\u03b1), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis, 2016; 249: 36-43","DOI":"10.1016\/j.atherosclerosis.2016.02.029"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Yokote K, Yamashita S, Arai H, Araki E, Suganami H, Ishibashi S. A pooled analysis of pemafibrate Phase II\/III clinical trials indicated significant improvement in glycemic and liver function-related parameters. Atheroscler Suppl, 2018; 32: 154-155","DOI":"10.1016\/j.atherosclerosissup.2018.04.470"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Dasarathy S, Dasarathy J, Khiyami A, Yerian L, Hawkins C, Sargent R et al. Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis. J Clin Gastroenterol, 2015; 49: 137-144","DOI":"10.1097\/MCG.0000000000000099"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM et al. Triglyceride lowering with pemafibrate to reduce cardiovascular risk. N Engl J Med, 2022; 387: 1923-1934","DOI":"10.1056\/NEJMoa2210645"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nakajima A, Eguchi Y, Yoneda M, Imajo K, Tamaki N, Suganami H et al. Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), versus placebo in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther, 2021; 54: 1263-1277","DOI":"10.1111\/apt.16596"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Sugimoto R, Iwasa M, Eguchi A, Tamai Y, Shigefuku R, Fujiwara N et al. Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients. Front Med (Lausanne), 2023; 10: 1073025","DOI":"10.3389\/fmed.2023.1073025"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Takeda Y, Sakuma I, Hiramitsu S, Okada M, Ueda S, Sakurai M. The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study). Front Cardiovasc Med, 2023; 10: 1094100","DOI":"10.3389\/fcvm.2023.1094100"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Takakusagi S, Sato K, Marubashi K et al. Impact of M2BPGi on the Hepatocarcinogenesis after the Combination Therapy with Daclatasvir and Asunaprevir for Hepatitis C. Biomedicines, 2021; 9: 660","DOI":"10.3390\/biomedicines9060660"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Migita K, Horai Y, Kozuru H et al. Serum cytokine profiles and Mac-2 binding protein glycosylation isomer (M2BPGi) level in patients with autoimmune hepatitis. Medicine (Baltimore), 2018; 97: e13450","DOI":"10.1097\/MD.0000000000013450"},{"key":"29","unstructured":"29) The Japanese Society of Gastroenterology. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020. 2nd ed. Nankodo, available at https: \/\/www.jsge.or.jp\/guideline\/guideline\/"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 2023; 77: 1797-1835","DOI":"10.1097\/HEP.0000000000000323"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Rinella ME, Dufour JF, Anstee QM, Goodman Z, Younossi Z, Harrison SA et al. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. J Hepatol, 2022; 76: 536-548","DOI":"10.1016\/j.jhep.2021.10.029"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/31\/11\/31_64896\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T04:38:23Z","timestamp":1730522303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/31\/11\/31_64896\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.64896","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]},"article-number":"64896"}}